Get the Stockscreener App
36.50
4.41%
1.54
After Hours:
36.53
0.03
+0.08%
Cogent Biosciences Inc stock is traded at $36.50, with a volume of 2.27M.
It is up +4.41% in the last 24 hours and down -8.68% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$34.96
Open:
$35.66
24h Volume:
2.27M
Relative Volume:
1.08
Market Cap:
$5.92B
Revenue:
-
Net Income/Loss:
$-328.94M
P/E Ratio:
-14.91
EPS:
-2.4487
Net Cash Flow:
$-266.00M
1W Performance:
+6.20%
1M Performance:
-8.68%
6M Performance:
+174.64%
1Y Performance:
+428.99%
1-Day Range:
$35.66
$37.04
1-Week Range:
$32.70
$37.04
52-Week Range:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
36.50 | 5.67B | 0 | -328.94M | -266.00M | -2.4487 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Nov-10-25 | Upgrade | Stifel | Hold → Buy |
| Nov-10-25 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - AOL.com
Aug Analyst Calls: Is Cogent Biosciences Inc forming a double bottomPortfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn
A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions - Yahoo Finance
Trading the Move, Not the Narrative: (COGT) Edition - Stock Traders Daily
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding - AOL.com
RTW Investments Increases Cogent Biosciences Stake to 2.7% of PortfolioNews and Statistics - IndexBox
Kynam Capital Sells $48M in Cogent Biosciences Shares | Q4 2025 Portfolio UpdateNews and Statistics - IndexBox
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - The Motley Fool
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - AOL.com
Biotech share surges 372% before being sold as latest selection climbs 40% in 2026 - Bitget
FDA accepts Cogent’s drug filing for treatment of rare blood disorder - MSN
Cogent Biosciences stock climbs after FDA accepts key drug application - MSN
HC Wainwright Analysts Lift Earnings Estimates for COGT - MarketBeat
Is Cogent Biosciences (COGT) one of the best multibagger stocks to buy according to billionaires? - MSN
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Ascendis Pharma (ASND) - The Globe and Mail
COGT Forecast, Price Target & Analyst Ratings | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
What Cogent Biosciences (COGT)'s FDA Acceptance of Bezuclastinib NDA Means For Shareholders - Yahoo Finance
COGT Shares Climb After FDA Accepts Bezuclastinib NDA for Non-Advanced SM - Bitget
Technical Analysis: What is the long term forecast for Cogent Biosciences Inc stockMarket Sentiment Report & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
COGT: Wedbush Reiterates Outperform Rating with $55 Price Target - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush - MarketBeat
Cinctive Capital Management LP Buys Shares of 111,058 Cogent Biosciences, Inc. $COGT - MarketBeat
Boothbay Fund Management LLC Cuts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Valuation In Focus After FDA Accepts Bezuclastinib NDA For Systemic Mastocytosis - simplywall.st
Raymond James Maintains Strong Buy for Cogent Biosciences (COGT) March 2026 - Meyka
Jefferies Initiates Buy Rating for Cogent Biosciences (COGT) wit - GuruFocus
Cogent Biosciences assumed with a Buy at Jefferies - TipRanks
Why Is Cogent Biosciences Stock Surging Monday?Cogent Biosciences (NASDAQ:COGT) - Benzinga
Cogent Biosciences (NASDAQ:COGT) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Shares Gap UpHere's Why - MarketBeat
Cogent Biosciences, Inc. shares surged 7.2% in pre-market trading after the U.S. Food and Drug Administration (FDA) officially accepted its new drug application for a rare disease treatment and will initiate the review process. - Bitget
Cogent Biosciences shares are trading higher ... - Benzinga
Cogent Biosciences (COGT) FDA Update on Bezuclastinib for NonAdv - GuruFocus
Cogent Biosciences Says FDA Accepted Marketing Application for Bezuclastinib in Non-Advanced Systemic Mastocytosis - marketscreener.com
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - The Manila Times
Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm) - TradingView
HighVista Strategies LLC Acquires 179,219 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. $COGT Shares Acquired by Fairmount Funds Management LLC - MarketBeat
Commodore Capital LP Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Boone Capital Management LLC Takes $13.57 Million Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires? - Insider Monkey
Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches - MarketBeat
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned - AOL.com
(COGT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cogent Biosciences (COGT) Valuation Check After New SUMMIT Trial Results For Bezuclastinib - Sahm
Will Cogent Biosciences Inc benefit from AI trends2025 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
JPMorgan raises Cogent Biosciences (COGT) PT to $67 on sector model update - MSN
Cogent Biosciences (COGT) advances bezuclastinib-sunitinib combination with breakthrough therapy designation (BTD) - MSN
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):